CD38 and neoplasm: The current status of the field points to CD38 as capable of shifting the local tumor metabolic microenvironment from pro-inflammatory to anti-inflammatory, indicating CD38 as a potential mechanism of resistance to currently approved immunotherapy agents, such as PD(L)-1 blocking antibodies.